HomeNewsBusinessReal EstateDelhi-NCR, Mumbai and Pune see a faster return to office as COVID ebbs

Delhi-NCR, Mumbai and Pune see a faster return to office as COVID ebbs

Employee attendance in these three cities is inching towards pre-pandemic levels, says a report by Colliers

March 31, 2022 / 16:03 IST
Story continues below Advertisement
Representative image
Representative image

Employees in Delhi and its suburbs, Mumbai and Pune are returning to the workplace at a faster pace compared to other cities, as offices reopen with coronavirus infections at their lowest in almost two years.

The National Capital Region (NCR), of which Delhi is a part, Mumbai and Pune have seen a steady increase in visits to workplaces and are almost inching towards pre-pandemic levels, a study by leading commercial real estate brokerage Colliers has found.

Story continues below Advertisement

“Returning to the workplace has been a running theme for the last two years, soon after every wave. However, we are seeing companies opening the office with greater fervour only now,” said Ramesh Nair, CEO, India and Managing Director, Market Development, Asia, Colliers.

Colliers studied the key trends emerging from the Google Covid-19 Community Mobility Reports to understand the change in patterns of visits to workplaces in top six cities.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show